Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
STAR-EV
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
- NCT06394570 ↗
- Recruiting
- University of Texas Southwestern Medical Center
- Standard
We haven't built an HCP commentary report on STAR-EV (enfortumab vedotin in localized bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on STAR-EV so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Stereotactic Treatment With neoAdjuvant Radiotherapy and Enfortumab Vedotin: a Phase I/II Study With Safety Lead-In for Localized Bladder Cancer (STAR-EV)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Bladder Cancer
- Interventions
- Enfortumab vedotin
- Arms
- Dose Level 0 · Experimental
- Dose Level 1 · Experimental
- Dose Level 2 · Experimental
- Enrollment
- 19 (estimated)
- Primary outcomes
- Maximum Tolerated Dose (MTD) Regimen
- Pathologic Complete response rate at radical cystectomy
- Sponsor
- University of Texas Southwestern Medical Center with Astellas Pharma Inc
- Start
- Sep 10, 2024
- Primary completion
- Sep 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06394570 · updated Sep 30, 2026